ZTS stock analysis

What happened: Zoetis Inc. (ZTS), a leading animal health company, saw a reduction in price objective by Citi analysts from $145 to $112, maintaining a "Buy" rating. This followed a reduction in estimates after the company's Q1 2023 results. Despite this, a bullish thesis on ZTS was published, highlighting its wide moat and attractive valuation with trailing and forward P/E ratios of 19.52 and 16.75 respectively.

Market impact: The animal health sector, particularly competitors like Merck & Co. (MRK) and Eli Lilly and Company (LLY) with animal health divisions, may face increased scrutiny due to Zoetis' valuation changes. Investors may reassess the sector's growth prospects and pricing power, potentially impacting other stocks in the space.

What to watch next: Zoetis' Q2 2023 earnings release on July 26 will provide insight into the company's performance and validate or refute the bullish thesis. Additionally, any updates on Citi's or other analysts' price targets and ratings will influence investor sentiment. Lastly, monitor regulatory decisions on Zoetis' pipeline, such as the FDA's action on its new animal vaccine candidates.